A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Public ClinicalTrials.gov record NCT03236857. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.
Study identification
- NCT ID
- NCT03236857
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 143 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 0 Years to 25 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 7, 2017
- Primary completion
- Apr 18, 2023
- Completion
- Apr 18, 2023
- Last update posted
- May 21, 2023
2017 – 2023
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univ California, San Francisco /ID# 163460 | San Francisco | California | 94143-2204 | — |
| Children's Hospital Colorado /ID# 161551 | Aurora | Colorado | 80045 | — |
| Children's Healthcare of Atlan /ID# 161552 | Atlanta | Georgia | 30322 | — |
| Dana-Farber Cancer Institute /ID# 163440 | Boston | Massachusetts | 02215 | — |
| Memorial Sloan Kettering Cancer Center-Koch Center /ID# 163444 | New York | New York | 10065-6007 | — |
| Cincinnati Children's Hospital /ID# 161550 | Cincinnati | Ohio | 45229 | — |
| Children's Hospital of Philadelphia /ID# 163445 | Philadelphia | Pennsylvania | 19104 | — |
| St Jude Children's Research Hospital /ID# 163447 | Memphis | Tennessee | 38105 | — |
| Primary Children's /ID# 164399 | Salt Lake City | Utah | 84113 | — |
| Seattle Children's Hospital /ID# 163459 | Seattle | Washington | 98105 | — |
| Medical College of Wisconsin /ID# 163461 | Milwaukee | Wisconsin | 53226-3522 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03236857, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2023 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03236857 live on ClinicalTrials.gov.